JP3193205B2 - 好酸球増多抑制剤 - Google Patents

好酸球増多抑制剤

Info

Publication number
JP3193205B2
JP3193205B2 JP21804393A JP21804393A JP3193205B2 JP 3193205 B2 JP3193205 B2 JP 3193205B2 JP 21804393 A JP21804393 A JP 21804393A JP 21804393 A JP21804393 A JP 21804393A JP 3193205 B2 JP3193205 B2 JP 3193205B2
Authority
JP
Japan
Prior art keywords
histamine
globulin
agent
present
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP21804393A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0753406A (ja
Inventor
春夫 吉井
有理子 深田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Priority to JP21804393A priority Critical patent/JP3193205B2/ja
Priority to TW083106994A priority patent/TW258664B/zh
Priority to KR1019940019333A priority patent/KR100275174B1/ko
Priority to CN94109522A priority patent/CN1127983C/zh
Priority to US08/287,249 priority patent/US5780026A/en
Priority to EP94112427A priority patent/EP0646376B1/en
Priority to AT94112427T priority patent/ATE192655T1/de
Priority to DE69424362T priority patent/DE69424362T2/de
Priority to ES94112427T priority patent/ES2146240T3/es
Publication of JPH0753406A publication Critical patent/JPH0753406A/ja
Priority to US09/840,331 priority patent/US6566386B2/en
Application granted granted Critical
Publication of JP3193205B2 publication Critical patent/JP3193205B2/ja
Priority to CNA011244763A priority patent/CN1471974A/zh
Priority to CNA011244771A priority patent/CN1471975A/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP21804393A 1993-08-09 1993-08-09 好酸球増多抑制剤 Expired - Fee Related JP3193205B2 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤
TW083106994A TW258664B (enExample) 1993-08-09 1994-07-30
KR1019940019333A KR100275174B1 (ko) 1993-08-09 1994-08-05 면역조정, 항염증제
US08/287,249 US5780026A (en) 1993-08-09 1994-08-08 Immunomodulating and antiinflammatory agent
CN94109522A CN1127983C (zh) 1993-08-09 1994-08-08 免疫调节、抗炎症剂
AT94112427T ATE192655T1 (de) 1993-08-09 1994-08-09 Verwendung von histamin-gamma-globulin zur herstellung eines immunomodulierenden und antiinflammatorischen agens
EP94112427A EP0646376B1 (en) 1993-08-09 1994-08-09 Use of histamine-added gamma-globulin for the manufacture of an immunomodulating and antiinflammatory agent
DE69424362T DE69424362T2 (de) 1993-08-09 1994-08-09 Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens
ES94112427T ES2146240T3 (es) 1993-08-09 1994-08-09 Agente inmunomodulador y antiinflamatorio.
US09/840,331 US6566386B2 (en) 1993-08-09 2001-04-23 Immunomodulating and antiinflammatory agent
CNA011244763A CN1471974A (zh) 1993-08-09 2001-08-01 抗炎症剂
CNA011244771A CN1471975A (zh) 1993-08-09 2001-08-01 免疫调节剂

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP21804393A JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2001113839A Division JP2001348342A (ja) 2001-04-12 2001-04-12 免疫調整・抗炎症剤

Publications (2)

Publication Number Publication Date
JPH0753406A JPH0753406A (ja) 1995-02-28
JP3193205B2 true JP3193205B2 (ja) 2001-07-30

Family

ID=16713756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP21804393A Expired - Fee Related JP3193205B2 (ja) 1993-08-09 1993-08-09 好酸球増多抑制剤

Country Status (9)

Country Link
US (1) US5780026A (enExample)
EP (1) EP0646376B1 (enExample)
JP (1) JP3193205B2 (enExample)
KR (1) KR100275174B1 (enExample)
CN (3) CN1127983C (enExample)
AT (1) ATE192655T1 (enExample)
DE (1) DE69424362T2 (enExample)
ES (1) ES2146240T3 (enExample)
TW (1) TW258664B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤
US6566386B2 (en) 1993-08-09 2003-05-20 Nippon Zoki Pharmaceutical Co., Ltd. Immunomodulating and antiinflammatory agent
IT1278052B1 (it) * 1995-03-14 1997-11-17 Mendes Srl Uso delle immunoglobuline della classe g, in particolare delle immunoglobuline per uso endovenoso o per uso intramuscolare, per
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
JPH0959180A (ja) * 1995-08-11 1997-03-04 Nippon Zoki Pharmaceut Co Ltd 活性化免疫グロブリン
US5961969A (en) * 1996-05-14 1999-10-05 Maxim Pharmaceuticals, Inc. Stable circulating histamine levels
US6071942A (en) 1996-05-14 2000-06-06 Maxim Pharmaceuticals, Inc. Elevation of circulating blood histamine levels
JPH10212246A (ja) 1997-01-30 1998-08-11 Nippon Zoki Pharmaceut Co Ltd 経口投与用製剤
US7232830B2 (en) 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
JP2000143537A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 細胞接着分子発現抑制剤
JP2000143536A (ja) * 1998-11-13 2000-05-23 Nippon Zoki Pharmaceut Co Ltd 抗浮腫剤
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
DE19944122A1 (de) * 1999-09-15 2001-03-29 Wolfgang Loh Histamin-Immunglobulin-Komplexe zur Behandlung von entzündlichen Erkrankungen bei Säugetieren
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20090317357A1 (en) * 2003-02-24 2009-12-24 Lawrence Steinman Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents
EP2671508B1 (en) 2005-04-28 2020-09-16 Proteus Digital Health, Inc. Pharma-informatics system
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質（ｒａｐ）結合体の投与による肝障害の処置
EP2142200B1 (en) 2007-05-10 2012-05-16 Rajesh Shah Homeopathy-based formulation
ES2919563T3 (es) 2009-02-20 2022-07-27 Enhanx Biopharm Inc Sistema de administración de medicamentos a base de glutatión
KR20180114970A (ko) 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5585526A (en) * 1978-12-23 1980-06-27 Nippon Zoki Pharmaceut Co Ltd Remedy for allergic disease
US4704273A (en) * 1982-05-17 1987-11-03 Mcmichael John Methods and materials for treatment of rheumatoid arthritis
US4705685A (en) * 1982-05-17 1987-11-10 Mcmichael John Methods and materials for treatment of disease states involving immunological factors
US4705687A (en) * 1985-06-17 1987-11-10 Ortho Pharmaceutical (Canada) Ltd. Treatment of autoimmune diseases such as rheumatoid arthritis with suppressor factor
US5244902A (en) * 1989-08-21 1993-09-14 Beth Israel Hospital Association Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
IT1237475B (it) * 1989-10-06 1993-06-07 Allergeni modificati chimicamente e procedimento per la loro preparazione
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JP3193205B2 (ja) * 1993-08-09 2001-07-30 日本臓器製薬株式会社 好酸球増多抑制剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｆａｒｍａｃｉａ，Ｖｏｌ．２６、Ｎｏ．１（１９７８）Ｐ．９−１２

Also Published As

Publication number Publication date
TW258664B (enExample) 1995-10-01
KR950005323A (ko) 1995-03-20
KR100275174B1 (ko) 2000-12-15
JPH0753406A (ja) 1995-02-28
CN1471974A (zh) 2004-02-04
US5780026A (en) 1998-07-14
CN1471975A (zh) 2004-02-04
EP0646376A1 (en) 1995-04-05
CN1127983C (zh) 2003-11-19
DE69424362D1 (de) 2000-06-15
EP0646376B1 (en) 2000-05-10
CN1121430A (zh) 1996-05-01
DE69424362T2 (de) 2000-10-19
ES2146240T3 (es) 2000-08-01
ATE192655T1 (de) 2000-05-15

Similar Documents

Publication Publication Date Title
KR100275174B1 (ko) 면역조정, 항염증제
LANGE et al. Changes in serum complement during the course and treatment of glomerulonephritis
Rodriguez et al. Antimitochondrial antibodies in jaundice following drug administration
Brugarolas et al. Treatment of cancer by an inducer of reverse transformation
Humphrey et al. The use of [14C] amino acids to study sites and rates of antibody synthesis in living hyperimmune rabbits
JP2746832B2 (ja) 眼局所抗アレルギー剤
JP2000143537A (ja) 細胞接着分子発現抑制剤
US6187803B1 (en) Drug preparation for oral administration
EP0758656B1 (en) Immunoglobulin activated by mixing with a histamine component
US6566386B2 (en) Immunomodulating and antiinflammatory agent
JP2001348342A (ja) 免疫調整・抗炎症剤
Woodward et al. Periosteal new bone formation in polyarteritis nodosa. A syndrome involving the lower extremities
EP1002544A1 (en) Anti-edema agent
JPH1053537A (ja) 活性化免疫グロブリン
Hurtado et al. Inhibition of Allergic Reactions by a New Antiallergic Drug, LC-6 (Trans-2, 3b, 4, 5, 7, 8b, 9, 10-Octahydronaphthol [1, 2-c: 5, 6-c′] Dipyrazole) I. Inhibition of the Rat Reaginic Passive Cutaneous Anaphylaxis
JPS60209532A (ja) 若年性関節リウマチ治療剤
Quiroz-Mercado et al. Effect of chloroquine on experimental melanin-protein-induced uveitis in Lewis rats
HARTEN et al. Allergy Abstracts
JPH10279498A (ja) 慢性関節リウマチ治療剤
JPS6238329B1 (enExample)

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees